Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: A systematic narrative review

Reproductive Sciences

Volumn 22, Issue 5, 2015, Pages 519-526

  Iwase, Akira ^a,b   Nakamura, Tomoko ^a   Nakahara, Tatsuo ^a   Goto, Maki ^a   Kikkawa, Fumitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

anti M llerian hormone; chemotherapy; oncofertility; ovarian reserve

Indexed keywords

FOLLITROPIN; MUELLERIAN INHIBITING FACTOR; SEX HORMONE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

AUTOIMMUNE DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CHILDHOOD CANCER; FEMALE FERTILITY; HEMATOLOGIC MALIGNANCY; HORMONE BLOOD LEVEL; HUMAN; MEASUREMENT; OVARIAN RESERVE; OVARY FUNCTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; DOWN REGULATION; DRUG EFFECTS; FEMALE; FEMALE INFERTILITY; FERTILITY PRESERVATION; METABOLISM; OVARY; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RADIATION INJURIES; RADIATION RESPONSE; RADIOTHERAPY; RISK FACTOR;

ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; BIOMARKERS; DOWN-REGULATION; FEMALE; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; OVARIAN RESERVE; OVARY; PREDICTIVE VALUE OF TESTS; RADIATION INJURIES; RADIOTHERAPY; RISK FACTORS;

EID: 84930709963     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114549856     Document Type: Review

References (57)

1. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006 ; 12 (6). 685-718
2. Bancsi LF, Broekmans FJ, Mol BW, Habbema JD, te Velde ER. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril. 2003 ; 79 (5). 1091-1100
3. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013 ; 99 (4). 963-969
4. Loh JS, Maheshwari A. Anti-Mullerian hormone - is it a crystal ball for predicting ovarian ageing?. Hum Reprod. 2011 ; 26 (11). 2925-2932
5. Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002 ; 143 (3). 1076-1084
6. Weenen C, Laven JS, Von Bergh AR, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004 ; 10 (2). 77-83
7. Anderson RA, Nelson SM, Wallace WH. Measuring anti-Mullerian hormone for the assessment of ovarian reserve: when and for whom is it indicated?. Maturitas. 2012 ; 71 (1). 28-33
8. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002 ; 77 (2). 357-362
9. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003 ; 18 (2). 323-327
10. van Rooij IA, Broekmans FJ, Scheffer GJ, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005 ; 83 (4). 979-987
11. La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010 ; 16 (2). 113-130
12. van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010 ; 25 (1). 221-227
13. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000 ; 283 (15). 2008-2012
14. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006 ; 24 (18). 2917-2931
15. McLaren JF, Bates GW. Fertility preservation in women of reproductive age with cancer. Am J Obstet Gynecol. 2012 ; 207 (6). 455-462
16. Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol. 2010 ; 28 (31). 4683-4686
17. Lutchman Singh K, Muttukrishna S, Stein RC, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007 ; 96 (12). 1808-1816
18. Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010 ; 94 (2). 638-644
19. Su HI, Sammel MD, Green J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010 ; 116 (3). 592-599
20. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011 ; 96 (5). 1336-1343
21. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006 ; 21 (10). 2583-2592
22. Anders C, Marcom PK, Peterson B, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008 ; 26 (3). 286-295
23. Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Impact of breast cancer on anti-Mullerian hormone levels in young women. Breast Cancer Res Treat. 2013 ; 137 (2). 571-577
24. Lee S, Ozkavukcu S, Heytens E, Moy F, Alappat RM, Oktay K. Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J Assist Reprod Genet. 2011 ; 28 (7). 651-656
25. Rosendahl M, Andersen CY, Ernst E, et al. Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Hum Reprod. 2008 ; 23 (11). 2475-2483
26. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology. 2007 ; 12 (2). 141-147
27. van Beek RD, van den Heuvel-Eibrink MM, Laven JS, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab. 2007 ; 92 (10). 3869-3874
28. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online. 2010 ; 20 (2). 280-285
29. Lie Fong S, Lugtenburg PJ, Schipper I, et al. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod. 2008 ; 23 (3). 674-678
30. Lawrenz B, Fehm T, von Wolff M, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma - evaluation by using antimullerian hormone and retrieved oocytes. Fertil Steril. 2012 ; 98 (1). 141-144
31. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod. 2003 ; 18 (11). 2368-2374
32. Lie Fong S, Laven JS, Hakvoort-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod. 2009 ; 24 (4). 982-990
33. van Waas M, Neggers SJ, Te Winkel ML, Beishuizen A, Pieters R, van den Heuvel-Eibrink MM. Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma. Ann Oncol. 2012 ; 23 (6). 1626-1632
34. Hamre H, Kiserud CE, Ruud E, Thorsby PM, Fossa SD. Gonadal function and parenthood 20 years after treatment for childhood lymphoma: a cross-sectional study. Pediatr Blood Cancer. 2012 ; 59 (2). 271-277
35. Morse H, Elfving M, Lindgren A, Wolner-Hanssen P, Andersen CY, Ora I. Acute onset of ovarian dysfunction in young females after start of cancer treatment. Pediatr Blood Cancer. 2013 ; 60 (4). 676-681
36. Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013 ; 99 (2). 477-483
37. Gracia CR, Sammel MD, Freeman E, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril. 2012 ; 97 (1). 134-140 e131
38. Cuny A, Trivin C, Brailly-Tabard S, et al. Inhibin B and anti-Mullerian hormone as markers of gonadal function after treatment for medulloblastoma or posterior fossa ependymoma during childhood. J Pediatr. 2011 ; 158 (6). 1016-1022. e1011
39. Iwase A, Sugita A, Hirokawa W, et al. Anti-Mullerian hormone as a marker of ovarian reserve in patients with ovarian malignancies who have undergone fertility-preserving surgery and chemotherapy. Gynecol Endocrinol. 2013 ; 29 (4). 357-360
40. Iwase A, Sugita A, Hirokawa W, et al. Anti-Mullerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia. Eur J Obstet Gynecol Reprod Biol. 2013 ; 167 (2). 194-198
41. Mok CC, Chan PT, To CH. Anti-mullerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013 ; 65 (1). 206-210
42. Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Mullerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013 ; 98 (9). 3785-3792
43. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 ; 69 (4). 631-637
44. Franco JG, Oliveira JB, Petersen CG, Mauri AL, Baruffi R, Cavagna M. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility. Med Hypotheses. 2012 ; 78 (4). 442-445
45. Dieudonne AS, Vandenberghe J, Geerts I, et al. Undetectable antimullerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor. Menopause. 2011 ; 18 (7). 821-824
46. Jantke A, Rendtorff R, Dittrich R, et al. Association between self-reported questionnaire data on fertility and results of hormone analyses in women after childhood cancer: a cross-sectional study. J Obstet Gynaecol Res. 2012 ; 38 (10). 1254-1259
47. Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH. Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab. 2012 ; 97 (6). 2059-2067
48. Brouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ. Levels of serum anti-Mullerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 ; 65 (9). 1534-1538
49. Domingues TS, Rocha AM, Serafini PC. Tests for ovarian reserve: reliability and utility. Curr Opin Obstet Gynecol. 2010 ; 22 (4). 271-276
50. Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. Maturitas. 2009 ; 63 (4). 280-291
51. Li HW, Ng EH, Wong BP, Anderson RA, Ho PC, Yeung WS. Correlation between three assay systems for anti-Mullerian hormone (AMH) determination. J Assist Reprod Genet. 2012 ; 29 (12). 1443-1446
52. Rustamov O, Smith A, Roberts SA, et al. The measurement of anti-Mullerian hormone: a critical appraisal. J Clin Endocrinol Metab. 2014 ; 99 (3). 723-732
53. Decanter C, Peigne M, Mailliez A, et al. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive anti-Mullerian hormone assay. Fertil Steril. 2014 ; 102 (2). 483-487
54. Su HI, Sammel MD, Homer MV, Bui K, Haunschild C, Stanczyk FZ. Comparability of antimullerian hormone levels among commercially available immunoassays. Fertil Steril. 2014 ; 101 (6). 1766-1772.e1761
55. Welsh P, Smith K, Nelson SM. A single-centre evaluation of two new anti-Mullerian hormone assays and comparison with the current clinical standard assay. Hum Reprod. 2014 ; 29 (5). 1035-1041
56. Donnez J, Squifflet J, Dolmans MM. Frozen-thawed ovarian tissue retransplants. Semin Reprod Med. 2009 ; 27 (6). 472-478
57. Smith GD, Serafini PC, Fioravanti J, et al. Prospective randomized comparison of human oocyte cryopreservation with slow-rate freezing or vitrification. Fertil Steril. 2010 ; 94 (6). 2088-2095